Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 9:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Unfractionated Heparin IV Clear all
Withdrawn Not applicable Interventional

Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients

NCT02707263
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
intravenous continuous infusion of heparin (IV UFH), Subcutaneous Heparin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 10, 2026, 9:49 PM EDT
Terminated Phase 1 Interventional

Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma

NCT01525069
View directory record Official record
Conditions
Cholangiocarcinoma, Liver Neoplasms
Interventions
Floxuridine, Dexamethasone, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 10, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Characterize the Effect of Heparin on Palifermin Activity

NCT01163097
View directory record Official record
Conditions
Oral Mucositis
Interventions
Palifermin, Heparin
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Sep 10, 2026, 9:49 PM EDT
Not listed Phase 1Phase 2 Interventional

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

NCT00293501
View directory record Official record
Conditions
Kidney Cancer
Interventions
tinzaparin sodium
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Chicago, Illinois • Lebanon, New Hampshire • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 10, 2026, 9:49 PM EDT
Completed Phase 2 Interventional

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome

NCT00932100
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
REG1, Heparin
Drug
Lead sponsor
Regado Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
26
States / cities
Huntsville, Alabama • Sacramento, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Sep 10, 2026, 9:49 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)

NCT00543400
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
M118, Unfractionated Heparin
Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
19 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
37
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 10, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI

NCT00464087
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
Bridgeport, Connecticut • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Sep 10, 2026, 9:49 PM EDT
Completed Phase 3 Interventional

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

NCT01076764
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Otamixaban, Placebo (for Otamixaban), UFH, Placebo (for UFH), Eptifibatide, Placebo (for Eptifibatide)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
13,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
107
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 10, 2026, 9:49 PM EDT
Withdrawn Not applicable Interventional

Fixed Low-dose Heparin Versus Standard Adjusted-dose Heparin Infusion in Adults Receiving Venovenous ECMO With a Heparin Bonded Circuit.

NCT02966080
View directory record Official record
Conditions
Acute Respiratory Failure, Extracorporeal Membrane Oxygenation Complication, Bleeding
Interventions
HEP-IV
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 10, 2026, 9:49 PM EDT
Terminated Phase 3 Interventional Results available

Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

NCT04571645
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Dociparstat, Control
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Orange, California • Westwood, Kansas • Louisville, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2024 · Synced Sep 10, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Results available

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

NCT00331162
View directory record Official record
Conditions
Graft Rejection
Interventions
Alemtuzumab, Anti-Thymocyte Globulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 10, 2026, 9:49 PM EDT
Completed Phase 2 Interventional Results available

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

NCT00061373
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Aspirin, tinzaparin sodium, eptifibatide
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 10, 2026, 9:49 PM EDT
Terminated Phase 4 Interventional Results available

Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery

NCT01547728
View directory record Official record
Conditions
Thrombophilia Due to Acquired Antithrombin III Deficiency
Interventions
Recombinant antithrombin (rhAT)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 10, 2026, 9:49 PM EDT
Suspended Phase 2 Interventional

Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin

NCT02501434
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial, Intracranial Aneurysm, Heparin-induced Thrombocytopenia Type II
Interventions
Continuous Low-Dose IV Unfractionated Heparin Infusion
Drug
Lead sponsor
Robert F. James
Other
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
New Haven, Connecticut • Gainesville, Florida • Tallahassee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 10, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?

NCT05021263
View directory record Official record
Conditions
Colo-rectal Cancer, Anesthesia
Interventions
IV Medications, placebo
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 10, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers

NCT01433705
View directory record Official record
Conditions
Heart Disease
Interventions
Rb-82 Pet scans, F-18 FDG Pet scans, N-13 ammonia Pet scans, Regadenoson
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 10, 2026, 9:49 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

NCT04389840
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Interventions
Dociparstat sodium, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Loxahatchee Groves, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 10, 2026, 9:49 PM EDT
Completed No phase listed Observational

Heparin or Enoxaparin in Patients With Cancer

NCT00004875
View directory record Official record
Conditions
Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
enoxaparin, heparin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2011 · Synced Sep 10, 2026, 9:49 PM EDT
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 10, 2026, 9:49 PM EDT
Terminated Phase 2 Interventional Results available

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

NCT04251715
View directory record Official record
Conditions
Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Dexamethasone, Floxuridine, Implanted Medical Device, Irinotecan, Leucovorin, Oxaliplatin, Quality-of-Life Assessment
Drug · Device · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 10, 2026, 9:49 PM EDT
Recruiting Phase 2 Interventional

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428
View directory record Official record
Conditions
Carcinoma, Non-small-Cell Lung
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Stanford, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 10, 2026, 9:49 PM EDT
Terminated Phase 3 Interventional

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

NCT00031837
View directory record Official record
Conditions
Pancreatic Cancer, Thromboembolism
Interventions
dalteparin, gemcitabine hydrochloride, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
13
States / cities
Mobile, Alabama • Denver, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 10, 2026, 9:49 PM EDT
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB

NCT00079508
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2011 · Synced Sep 10, 2026, 9:49 PM EDT
Completed Phase 3 Interventional

Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)

NCT00079586
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions
Heparin, Bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Sep 10, 2026, 9:49 PM EDT